← All trials
NCT04527250
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 16, 2020
- Primary completion
- Jul 31, 2021
- Completion date
- Aug 31, 2022
- First posted
- Aug 26, 2020
- Last posted
- Sep 18, 2020
- Enrollment
- 65
- Arms / groups
- 10 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Ascletis Pharmaceuticals Co., Ltd.Lead sponsor
- Central South UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.